Comcast Shares Undervalued at 4.4x EBITDA Following Planned Business Separation, Analyst Says
Comcast Corporation stock was assigned a Buy rating with a target price of $33.51, representing a potential 34.8% upside from its November 19 close of $24.86.
🧠AI AnalysisPhoto: Seeking Alpha
Key points
- Comcast given Buy rating with $33.51 target price
- Implies 34.8% upside from November 19 close of $24.86
- Valuation sits at 4.4x EBITDA for remaining business segments
Comcast Corporation shares are trading at an attractive valuation of 4.4 times EBITDA for the operations remaining after the company's planned business adjustments, according to a recent analyst report. The assessment set a target price of $33.51 on the stock, offering a significant 34.8% increase compared to the November 19 closing price of $24.86, which also factors in a $1.32 per share distribution.
For everyday investors watching media and telecommunications conglomerates, corporate restructuring often unlocks hidden value by separating slower-growth infrastructure from dynamic growth segments. This valuation highlights how the remaining enterprise could offer an appealing entry point for market participants focused on cash flow multiples.
What to watch next: Monitor further announcements regarding the operational separation timeline and execution details.
Source Seeking Alpha — seekingalpha.com/article/4970819-comcast-4-4x-ebitda-is-too-cheap-for-t… ↗
Read next
🧠AI AnalysisAnthropic IPO Momentum Fades as Stock Slips Below Opening Levels
Anthropic shares declined following a strong market debut, prompting market watchers to evaluate potential short-term downside risks.
📈MarketsBitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound
Bitcoin is hovering near a vital monthly support level, with technical analysts warning that a close below this threshold could risk a drop toward the $32,000 region.
🧠AI AnalysisBitcoin Tests $58,000 Put Wall Following Market Flush
Bitcoin is hovering near the $58,000 level after dropping to a low of $55,127, with traders closely monitoring key support and resistance zones tied to upcoming options e…
💼InvestingCG Oncology Fair Value Revised Following Phase 3 Clinical Results
Recent Phase 3 clinical data for CG Oncology's bladder cancer treatment has prompted a reevaluation of the company's stock, though analysts see limited room for further n…
🧠AI AnalysisMarket Brief24 AI Analysis: Volatility Shock Grips US Equities as High-Beta Sectors Plummet
US markets experienced an abrupt risk aversion shift for the week ending November 21, 2026, as the VIX volatility index surged to 35.90 and high-beta technology shares su…
💼InvestingBank of America Stock Drops 25% From Peak: Valuation Appeal Versus Competitor Pressure
Bank of America shares have slid 25% from their yearly high following a disappointing third-quarter earnings report, prompting everyday investors to weigh cheap valuation…